2024
EP.07C.10 Real-World Outcomes of Patients Treated with Neoadjuvant Immunotherapy for Resectable Non-Small Cell Lung Cancer
Ermer T, Kim S, Goldberg S, Zolfaghari E, Blasberg J, Boffa D, Herbst R, Politi K, Schalper K, Dacic S, Woodard G. EP.07C.10 Real-World Outcomes of Patients Treated with Neoadjuvant Immunotherapy for Resectable Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2024, 19: s543-s544. DOI: 10.1016/j.jtho.2024.09.1007.Peer-Reviewed Original Research
2022
Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer
Pichert MD, Canavan ME, Maduka RC, Li AX, Ermer T, Zhan PL, Kaminski M, Udelsman BV, Blasberg JD, Park HS, Goldberg SB, Boffa DJ. Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer. JAMA Network Open 2022, 5: e2224478. PMID: 35925606, PMCID: PMC9353596, DOI: 10.1001/jamanetworkopen.2022.24478.Peer-Reviewed Original ResearchConceptsStage III non-small cell lung cancerNon-small cell lung cancerClinical stage III non-small cell lung cancerUnresectable stage III non-small cell lung cancerPropensity-matched sampleGeneral US populationSurvival advantageCohort studyLung cancerMultivariable Cox proportional hazards modelsUS populationStage III lung cancerMedian age 66 yearsCox proportional hazards modelNational Cancer DatabaseEfficacy of immunotherapyAge 66 yearsProtocol rangesCell lung cancerClinical trial populationsProportional hazards modelTerms of ageImmunotherapy initiationImmunotherapy recipientsImmunotherapy useRevisiting Indications for Brain Imaging During the Clinical Staging Evaluation of Lung Cancer
Pichert MD, Canavan ME, Maduka RC, Li AX, Ermer T, Zhan PL, Kaminski M, Udelsman BV, Blasberg JD, Mase VJ, Dhanasopon AP, Boffa DJ. Revisiting Indications for Brain Imaging During the Clinical Staging Evaluation of Lung Cancer. JTO Clinical And Research Reports 2022, 3: 100318. PMID: 35540711, PMCID: PMC9079298, DOI: 10.1016/j.jtocrr.2022.100318.Peer-Reviewed Original ResearchPrevalence of brainBrain metastasesSummary stageBrain imagingN classificationIsolated brain metastasesNode-negative NSCLCRoutine brain imagingStage II NSCLCStage IV NSCLCClinical stage INational Cancer DatabaseEarly-stage NSCLCStage IAStage IIIAStage NSCLCStaging evaluationClinical stageLung cancerCancer DatabaseN stageNSCLCPatientsStage IMetastasis
2020
Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non–Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features
Pathak R, Goldberg SB, Canavan M, Herrin J, Hoag JR, Salazar MC, Papageorge M, Ermer T, Boffa DJ. Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non–Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features. JAMA Oncology 2020, 6: 1741-1750. PMID: 32940636, PMCID: PMC7499246, DOI: 10.1001/jamaoncol.2020.4232.Peer-Reviewed Original ResearchConceptsNode-negative non-small cell lung cancerHigh-risk pathologic featuresNon-small cell lung cancerAdjuvant chemotherapyCell lung cancerPathologic featuresTumor sizeSurvival benefitCohort studyLung cancerNode-negative NSCLCEarly-stage non-small cell lung cancerCox proportional hazards regression modelHigh-risk clinicopathologic featuresProportional hazards regression modelsNational Cancer DatabaseRetrospective cohort studyTreatment-naive patientsAdjuvant chemotherapy useHigh-risk featuresAssociation of survivalHazards regression modelsImmortal time biasChemotherapy useEligible patients